Advances in the treatment of hereditary transthyretin amyloidosis: A review

Research output: Contribution to journalReview article

Abstract

INTRODUCTION: Amyloid transthyretin amyloidosis (ATTR) is a progressive and often fatal disease caused by the buildup of mutated (hereditary ATTR [hATTR]; also known as ATTR variant [ATTRv]) or normal transthyretin (wild-type ATTR) throughout the body. Two new therapies-inotersen, an antisense oligonucleotide therapy, and patisiran, an RNA interference therapy-received marketing authorization and represent a significant advance in the treatment of amyloidosis. Herein, we describe the clinical presentation of ATTR, commonly used procedures in its diagnosis, and current treatment landscape for ATTR, with a focus on hATTR. METHODS: A PubMed search from 2008 to September 2018 was conducted to review the literature on ATTR. RESULTS: Until recently, there have been few treatment options for polyneuropathy of hATTR. Inotersen and patisiran substantially reduce the amyloidogenic precursor protein transthyretin and have demonstrated efficacy in patients with early- and late-stage disease and in slowing or improving neuropathy progression. In contrast, established therapies, such as liver transplantation, typically reserved for patients with early-stage disease, and tafamidis, indicated for the treatment of early-stage disease in Europe, or diflunisal, a nonsteroidal anti-inflammatory drug that is used off-label, are associated with side effects and/or unclear efficacy in certain patient populations. Thus, inotersen and patisiran are positioned to be the preferred therapeutic modalities. CONCLUSIONS: Important differences between inotersen and patisiran, including formulation, dosing, requirements for premedications, and safety monitoring, require an understanding and knowledge of each treatment for informed decision making.

Original languageEnglish (US)
Pages (from-to)e01371
JournalBrain and behavior
Volume9
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Familial Amyloidosis
Amyloid
Therapeutics
Prealbumin
Diflunisal
Amyloidosis, Hereditary, Transthyretin-Related
Amyloidogenic Proteins
Premedication
Polyneuropathies
Antisense Oligonucleotides
Amyloidosis
RNA Interference
Marketing
PubMed
Liver Transplantation
Decision Making
Anti-Inflammatory Agents

Keywords

  • amyloid
  • hATTR
  • inotersen
  • patisiran
  • transthyretin amyloidosis

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

Advances in the treatment of hereditary transthyretin amyloidosis : A review. / Gertz, Morie; Mauermann, Michelle M; Grogan, Martha; Coelho, Teresa.

In: Brain and behavior, Vol. 9, No. 9, 01.09.2019, p. e01371.

Research output: Contribution to journalReview article

@article{dca6459713b5471d8a99356a4a0d5fd2,
title = "Advances in the treatment of hereditary transthyretin amyloidosis: A review",
abstract = "INTRODUCTION: Amyloid transthyretin amyloidosis (ATTR) is a progressive and often fatal disease caused by the buildup of mutated (hereditary ATTR [hATTR]; also known as ATTR variant [ATTRv]) or normal transthyretin (wild-type ATTR) throughout the body. Two new therapies-inotersen, an antisense oligonucleotide therapy, and patisiran, an RNA interference therapy-received marketing authorization and represent a significant advance in the treatment of amyloidosis. Herein, we describe the clinical presentation of ATTR, commonly used procedures in its diagnosis, and current treatment landscape for ATTR, with a focus on hATTR. METHODS: A PubMed search from 2008 to September 2018 was conducted to review the literature on ATTR. RESULTS: Until recently, there have been few treatment options for polyneuropathy of hATTR. Inotersen and patisiran substantially reduce the amyloidogenic precursor protein transthyretin and have demonstrated efficacy in patients with early- and late-stage disease and in slowing or improving neuropathy progression. In contrast, established therapies, such as liver transplantation, typically reserved for patients with early-stage disease, and tafamidis, indicated for the treatment of early-stage disease in Europe, or diflunisal, a nonsteroidal anti-inflammatory drug that is used off-label, are associated with side effects and/or unclear efficacy in certain patient populations. Thus, inotersen and patisiran are positioned to be the preferred therapeutic modalities. CONCLUSIONS: Important differences between inotersen and patisiran, including formulation, dosing, requirements for premedications, and safety monitoring, require an understanding and knowledge of each treatment for informed decision making.",
keywords = "amyloid, hATTR, inotersen, patisiran, transthyretin amyloidosis",
author = "Morie Gertz and Mauermann, {Michelle M} and Martha Grogan and Teresa Coelho",
year = "2019",
month = "9",
day = "1",
doi = "10.1002/brb3.1371",
language = "English (US)",
volume = "9",
pages = "e01371",
journal = "Brain and Behavior",
issn = "2157-9032",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Advances in the treatment of hereditary transthyretin amyloidosis

T2 - A review

AU - Gertz, Morie

AU - Mauermann, Michelle M

AU - Grogan, Martha

AU - Coelho, Teresa

PY - 2019/9/1

Y1 - 2019/9/1

N2 - INTRODUCTION: Amyloid transthyretin amyloidosis (ATTR) is a progressive and often fatal disease caused by the buildup of mutated (hereditary ATTR [hATTR]; also known as ATTR variant [ATTRv]) or normal transthyretin (wild-type ATTR) throughout the body. Two new therapies-inotersen, an antisense oligonucleotide therapy, and patisiran, an RNA interference therapy-received marketing authorization and represent a significant advance in the treatment of amyloidosis. Herein, we describe the clinical presentation of ATTR, commonly used procedures in its diagnosis, and current treatment landscape for ATTR, with a focus on hATTR. METHODS: A PubMed search from 2008 to September 2018 was conducted to review the literature on ATTR. RESULTS: Until recently, there have been few treatment options for polyneuropathy of hATTR. Inotersen and patisiran substantially reduce the amyloidogenic precursor protein transthyretin and have demonstrated efficacy in patients with early- and late-stage disease and in slowing or improving neuropathy progression. In contrast, established therapies, such as liver transplantation, typically reserved for patients with early-stage disease, and tafamidis, indicated for the treatment of early-stage disease in Europe, or diflunisal, a nonsteroidal anti-inflammatory drug that is used off-label, are associated with side effects and/or unclear efficacy in certain patient populations. Thus, inotersen and patisiran are positioned to be the preferred therapeutic modalities. CONCLUSIONS: Important differences between inotersen and patisiran, including formulation, dosing, requirements for premedications, and safety monitoring, require an understanding and knowledge of each treatment for informed decision making.

AB - INTRODUCTION: Amyloid transthyretin amyloidosis (ATTR) is a progressive and often fatal disease caused by the buildup of mutated (hereditary ATTR [hATTR]; also known as ATTR variant [ATTRv]) or normal transthyretin (wild-type ATTR) throughout the body. Two new therapies-inotersen, an antisense oligonucleotide therapy, and patisiran, an RNA interference therapy-received marketing authorization and represent a significant advance in the treatment of amyloidosis. Herein, we describe the clinical presentation of ATTR, commonly used procedures in its diagnosis, and current treatment landscape for ATTR, with a focus on hATTR. METHODS: A PubMed search from 2008 to September 2018 was conducted to review the literature on ATTR. RESULTS: Until recently, there have been few treatment options for polyneuropathy of hATTR. Inotersen and patisiran substantially reduce the amyloidogenic precursor protein transthyretin and have demonstrated efficacy in patients with early- and late-stage disease and in slowing or improving neuropathy progression. In contrast, established therapies, such as liver transplantation, typically reserved for patients with early-stage disease, and tafamidis, indicated for the treatment of early-stage disease in Europe, or diflunisal, a nonsteroidal anti-inflammatory drug that is used off-label, are associated with side effects and/or unclear efficacy in certain patient populations. Thus, inotersen and patisiran are positioned to be the preferred therapeutic modalities. CONCLUSIONS: Important differences between inotersen and patisiran, including formulation, dosing, requirements for premedications, and safety monitoring, require an understanding and knowledge of each treatment for informed decision making.

KW - amyloid

KW - hATTR

KW - inotersen

KW - patisiran

KW - transthyretin amyloidosis

UR - http://www.scopus.com/inward/record.url?scp=85072352538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072352538&partnerID=8YFLogxK

U2 - 10.1002/brb3.1371

DO - 10.1002/brb3.1371

M3 - Review article

C2 - 31368669

AN - SCOPUS:85072352538

VL - 9

SP - e01371

JO - Brain and Behavior

JF - Brain and Behavior

SN - 2157-9032

IS - 9

ER -